Predict your next investment

HEALTHCARE | Drug Development
oncoimmune.com

See what CB Insights has to offer

Total Raised

$74M

Investors Count

7

Deal Terms

2

OncoImmune Funding, OncoImmune Valuation & OncoImmune Revenue

4 Fundings

OncoImmune's latest funding round was a Acquired for on November 23, 2020.

OncoImmune's valuation in January 2017 was $60.31M.

OncoImmune's latest post-money valuation is from November 2020.

Sign up for a free trial to see OncoImmune's valuations in November 2020 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/23/2020

Acquired

$99M

4

9/9/2020

Series B

$99M

10

4/2/2020

Unattributed VC

$99M

10

1/12/2017

Series A

$99M

$60.31M

10

Date

11/23/2020

9/9/2020

4/2/2020

1/12/2017

Round

Acquired

Series B

Unattributed VC

Series A

Amount

$99M

$99M

$99M

Investors

Valuation

$99M

$60.31M

Revenue

Sources

4

10

10

10

OncoImmune Deal Terms

2 Deal Terms

OncoImmune's deal structure is available for 2 funding rounds, including their Acquired from November 23, 2020.

Round

Acquired

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

OncoImmune Investors

7 Investors

OncoImmune has 7 investors. Merck & Co. invested in OncoImmune's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/23/2020

11/23/2020

1
Acquired

Corporation

New Jersey

00/00/0000

00/00/0000

3E Bioventures

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

GF Xinde Investment Management Co.

Subscribe to see more

Asset/Investment Management

China

00/00/0000

00/00/0000

Kaitai Capital

Subscribe to see more

Venture Capital

China

00/00/0000

00/00/0000

HM Capital

Subscribe to see more

Private Equity

Texas

First funding

11/23/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

11/23/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

3E Bioventures

GF Xinde Investment Management Co.

Kaitai Capital

HM Capital

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Venture Capital

Asset/Investment Management

Venture Capital

Private Equity

Location

New Jersey

California

China

China

Texas

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.